Shareholders of Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) will be pleased this week, given that the stock price is up... CAMBRIDGE, Mass. AP) — Akebia Therapeutics Inc. AKBA) on Thursday ...

AKEBIA THERAPEUTICS ($AKBA) posted quarterly earnings results on Thursday, March 13th. The company reported earnings of -$0.10 per share, missing estimates of -$0.08 ...

Akebia Therapeutics (AKBA) stock drops as the company disappoints with its Q4 earnings update despite revenue beats. Read more here.

Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to break-even earnings per share a year ago.

Commenting on the Vafseo launch, John P. Butler, Chief Executive Officer of Akebia (AKBA) said: “We believe Vafseo can be a new standard of care for the treatment of anemia due to chronic kidney ...

CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended ...